spacer
home > pmps > autumn 2018 > bracing for brexit
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Bracing for Brexit

PMPS:Can you summarise why Brexit will impact pharmacovigilance (PV)?

Dr Jackie Roberts: The decision and process of leaving the EU after the referendum vote had, and continues to have, a significant knock-on effect for UK-based businesses, particularly pharmaceutical manufacturers.

The industry relies on being able to manufacture, supply, and distribute across Europe, enabling products to reach patients quickly and safely with relative ease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jackie Roberts is the Executive Director responsible for regulatory, pharmacovigilance, medical, and healthcare compliance at Accord Healthcare. She is also the Qualified Person for pharmacovigilance at the company. She has a PhD in clinical pharmacology from Imperial College in London, UK, and an MBA with distinction from Warwick Business School, UK. Jackie’s experience spans the industry, contract research organisations, and the UK regulatory authority.
spacer
Dr Jackie Roberts
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers
 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement